一項(xiàng)大型臨床試驗(yàn)結(jié)果顯示，通過腹腔進(jìn)行化療能夠?qū)⑼砥诼殉舶┗颊叩纳鏁r(shí)間延長大約1年。

研究人員將新近診斷的III期卵巢癌患者隨機(jī)分成兩組:接受靜脈化療，或者接受靜脈和腹腔內(nèi)導(dǎo)管插入化療。 這項(xiàng)為期7年涉及400例患者的研究結(jié)果，發(fā)表在2006年1月5日《新英格蘭期刊》之上。

但是接受腹腔化療患者的副作用，包括血細(xì)胞計(jì)數(shù)減少和神經(jīng)系統(tǒng)疾病顯著增多，在治療期間的生活質(zhì)量明顯較差。需要接受支持治療或者出現(xiàn)手術(shù)并發(fā)癥、腎功能不全、或者左側(cè)結(jié)腸切除的患者，都不適合腹腔內(nèi)化療。205例入選患者之中只有86例能夠完成腹腔化療。

Combined Drug Method Best for Ovarian Cancer
 
A large clinical trial has shown that chemotherapy delivered into the abdomen increases survival in some women with advanced ovarian cancer by about one year.

The investigators randomly grouped women with newly diagnosed stage III ovarian cancer into two categories: those who would get all chemotherapy intravenously or those who would get chemotherapy both intravenously and intraperitoneal (IP) through a catheter inserted directly into the abdomen. The results, from a seven-year study of more than 400 patients, were reported in the January 5, 2006, issue of The New England Journal of Medicine.

However, side effects such as suppressed blood counts and neurologic problems were significantly worse for the group receiving abdominal chemotherapy, and they reported poorer quality of life during their treatment. Patients with adhesions or surgical complications, poor kidney function, and those who have had the left side of their colon removed during surgery are not good candidates for IP chemotherapy. Only 86 of the 205 patients enrolled for the abdominal therapy were able to complete the course.